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Abstract 
Vasomotor symptoms, such as hot flushes and night sweats, are very common during the 
menopausal transition. One of the important alternative treatments is foods or supplements enriched 
with phytoestrogens. 
Aim of the study 
To assess the efficacy, safety and acceptability of pometone supplements for 
reducing sweating, hot flushes and sleep disturbance in peri and postmenopausal women. 
Methods  
This cross sectional randomized clinical therapeutic trail involved 44 peri and postmenopausal 
women. All patients took oral pometone capsule 500mg twice daily for one month period.  
Result  
The mean of hot flush, sweating score before treatment was 8.11±1.72. After four weeks of 
treatment, it became 1.36 ±2.10; P value was < 0.0001. The mean of sleep disturbance score before 
treatment was 4.40±3.03. After four weeks of treatment, it become 1.22 ±1.80 ; P value was  < 0.0001 . 
No side effect was reported during the course of this study. 
Conclusion 
Pometone is effective, safe and cheep treatment to reduce hot flushes , night sweat and sleep 
disturbance in peri and postmenopausal women. 
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ةصلاخلا 
ضارعا  كرحملالايئاعو ،لثم ةنخاسلا تابهلا)ةرارحلاب روعشلا(  و ةعئاش ،يليللا قرعتلاادج ةيلاقتنلاا ةلحرملا للاخ  دعب ام
ثمطلا عاطقنا. تاجلاعلا نم دحاو ةليدبلا ةمهملا ةمعطلأا يه ةيئاذغلا تلامكملا وأ  ةينغلا .نيجورتساوتيافلاب 
ةساردلا نم فدهلا 
مييقتل يلاعفة ةملاسو ةيلوبقمو  نوتيموبلا نم دحلل  و ،قرعتلا مونلا بارطضاو ،ةنخاسلا تابهلايف سايلا نس دعبامو سايلا لوح نس 
 قرطلا 
  ةساردلا تنمضت44  نهئاطعا مت .سايلا نس دعبامو سايلا لوح نس يف ةأرما055  رهش ةدمل نوتيموب ءاود نم ايموي نيترم مغلم
.دحاو 
جئاتنلا 
 روعشلا لدعم نا  نم تاضيرملا ىدل ضفخنا قرعتلاو ةرارحلاب1.88 ىلا جلاعلا لبق8..1  لدعم ناو .جلاعلا نم رهش دعب
 نم ضفخنا مونلا يف تابارطضلأا4.4  ىلا جلاعلا لبق8.11 جلاعلا نم رهش دعب . 
جاتنتسلاا 
 مونلا تابارطضاو قرعتلاو ةرارحلاب روعشلا جلاعل صيخرو نيمأ ,رثؤم نوتيموبلا ناا دنعهدعبو سايلا نس لوح ءاسنل. 
لا تاممكلاةيحاتفم:ءاسنلا,مونلا بارطضا,ةنخاسلا تابهلا ,قرعتلا ,سايلا نس يف  نوتيموب. 
 
Introduction 
Natural menopause specifically, is confirmed after 12 consecutive months of 
amenorrhea in the absence of any obvious, pathological cause (NAMS).(2010). 
Surgical menopause results following surgical removal of the ovaries. In either 
instance, one result of the declining estrogen concentrations is the occurrence of 
vasomotor symptoms (VMS) that include hot flush and night sweats. Vasomotor 
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symptoms including hot flashes and night sweats occur in as many as 68.5% of 
women as a result of menopause (Blumel et al.,2011).  While the median duration of 
these symptoms is 4 years, approximately 10% of women continue to experience 
VMS as many as 12 years after their final menstrual period (Politi et al.,2008).  
Severe VMS occur in 10.8% of women in perimenopausal time frame, in 12.3% of 
women during early menopause (1-4 years), and in 11.5% of women in late 
menopause defined as greater than 5 years from the final menstrual period 
 (Blumel et al.,2011) 
          The prevalence and severity of VMS is greater in women who are surgically 
menopausal compared to women experiencing natural menopause (Politi et al.,2008).    
As such, VMS have a significant impact on the quality of life and overall physical 
health of women experiencing VMS, leading to their pursuance of treatment to 
alleviate these symptoms. Management of VMS includes lifestyle modifications, 
some herbal and vitamin supplements, hormonal therapies including estrogen and 
nonhormonal therapies including clonidine, gabapentin, and some of the serotonin-
norepinephrine reuptake inhibitors (Elena et al., 2012).  VMS are theorized to result 
from dysfunction in the woman’s tightly controlled temperature circuitry, leading to 
exaggerated activation of heat dissipation responses such as peripheral vasodilatation 
and sweating (Deecher et al.,2007). 
 
Hormone replacement therapy remains the most 
effective treatment for VMS. According to the most recent Cochrane review, hormone 
therapy reduces the frequency and severity of hot flashes by 75%-79 % (Maclennan et 
al.,2004). For decades, estrogen was used as a component of hormone replacement 
therapy to treat menopausal symptoms and for anticipated preventive health benefits 
in women with progesterone, or as a monotherapy hormone treatment in women after 
hysterectomy, but thereafter studies reported that long term estrogen increase the 
prevalence of cardiovascular events and breast cancer, many patients and researchers 
have looked into alternative treatments such as food or products containing 
phytoestrogens.
  
Phytoestrogens are weak plant derived estrogens that are structurally 
similar to estrogen hormones produced by the body and bind to the estrogen receptors, 
acting like hormone regulators (Betty, 2009). 
 
The food most commonly known to 
contain phytoestrogens is soy, but beans, peas, lentils, and whole grains and seeds, 
especially flaxseed, rye, and millet, also contain these plant estrogens (Somjen et al., 
2005). Pomegranate tree has been used extensively as indigenous medicine in many 
cultures, at least as far back as 1550 B.C (Wren, 1988) The oil from the seeds 
contains about 80% of a rare 18-carbon fatty acid, or punicic acid (Longtin., 2003). 
Also present in this oil are isoflavonic phytoestrogens (genistein & daidzein) and a 
phytoestrogenic coumestan called coumestrol
 
(Moneam  et al., 1988). Pomegranate is 
one of the only plants in nature known to contain the sex steroid estrone and has the 
highest botanical concentration of the steroid estrone at 14 mg/kg dried seed 
(Heftmann , 1966). The role of phytoestrogens has stimulated considerable interest 
since populations consuming a diet high in isoflavones such as the Japanese appear to 
have lower rates of menopausal vasomotor symptoms, cardiovascular disease, 
osteoporosis, and breast, colon, endometrial and ovarian cancers.
 
The normal 
Japanese diet contains 200mg of phytoestrogens per day in comparison to the average 
Western diet, which contains less than 1mg.
 
Efficacy for vasomotor symptom relief is 
lower than with traditional HRT (maximally 60-70% symptom reduction compared 
with 90-100% with traditional HRT).
 
Beneficial effects have been shown on 
cardiovascular risk markers such as lipids and arterial compliance and on bone 
markers (density) , with possible SERM (selective estrogen receptor modulator) type 
effects (Somjen et al., 2005).  Pomegranate juice and seed oil contain phytoestrogenic 
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compounds that have been shown to exhibit antioxidant activity (Schubert et al., 
1999). Exert anti-proliferative effects on human breast cancer cells (Kim et al., 2002),  
significant anti-tumor activity against human prostate cancer (Albrecht et al., 2004), 
 
and heart disease prevention (Aviram et al., 2004). Also, pomegranate has been 
recommended as medicinal food for treatment of Acquired Immune Deficiency 
System (AIDS) patients (Lee et al., 1998). 
 
 
Patients and Methods
 
This is a cross-sectional randomized clinical therapeutic trial done at private 
clinic for a period extended from January  2013 to January  2014, involving 44 
women; 7 of them were perimenopausal and the remaining 37 were postmenopausal, 
their age range from (40-65) years with means of 48.91 years ±6.38 SD. Four of the 
participitants had premature menopause. And 3 women had history of hysterectomy 
few months ago. They presented with hot flush, sweating and/or disturbances of their 
sleep. A verbal consent was obtained from all the participitants before the start of 
treatment. All the women took 500mg pometone capsules twice per day for a period 
of one month.  All the patients were asked to record the severity of their hot flush , 
night sweat on a visual analogue scale twice per week ,the scale consisted of a 10 cm 
horizontal line marked from 0 (denoting absent symptoms) to 10 (denoting worst 
symptoms) and sleep disturbance  by counting the numbers of awaking from sleep per 
night. Patients were assigned to receive 4 weeks of pometone capsule 500 mg twice 
per day. A reduction in scores of ≥ 50% was considered as the desired improvement 
in symptoms during treatment. Response to treatment was measured by using analysis 
of variance (ANOVA) test.  P value <0.05 was considered as level of significance. 
Result  
The mean hot flush, sweating score before treatment was 8.11±1.72. After one 
week of treatment, it  became 4.77±2.22. This score continued to decrease reaching to 
2.93±2.13 by the end of second week; at the end of 3ed week the score became 
1.68±2.12. The score continued to decrease reaching to 1.36 ±2.10 in the end of the 
fourth week. P value was < 0.0001,considered extremely significant as shown in table 
(1) and figure (1). 
 
Table (1): Comparison response (hot flushing,sweating) to pometone treatment with 
one week interval. P value <0.05 was considered as level of significance. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
95% 
Confidence 
Interval 
 
P 
 
SD 
Mean of Hot 
Flushing, 
Sweating 
 
No. 
 
 
Time 
 
 
2.124-4.556 P<0.001 1.72 8.11 44 Before Pair  I 
2.22 4.77 44 1
st
 week 
0.6238-3.056 <0.001 2.22 4.77 44 1
st
 week Pair  2 
2.13 2.93 44 2
nd
 week 
0.03378-2.466 <0.001 2.13 2.93 44 2
nd
 week Pair 3 
2.12 1.68 44 3
rd
 week 
-0.8962-1.536 P>0.05 2.12 1.68 44 3
rd
 week Pair  4 
2.10 1.36 44 4
th
 week 
5.534-7.966 P<0.001 1.70 8.11 44 Before Pair  5 
2.10 1.36 44 4
th
 week 
 
 
Journal of University of Babylon, Pure and Applied Sciences, Vol.(25), No.(5), 2017. 
1796 
 
 
 
Figure(1) patients response to treatment with one week interval. 
 
The mean of sleep disturbance (numbers of awaking from sleep) score before 
treatment was 4.40±3.03. After one week of treatment, it became 4±2.94. This score 
continued to decrease reaching to 2.70±2.47 by the end of second week; at the end of 
3ed week the score become 1.61±1.95. The score continued to decrease reaching to 
1.22 ±1.80 in the end of the fourth week. P value was < 0.0001,considered extremely 
significant as shown in table (2) and figure (2).  No side effect was reported during 
the course of this study. 
Table (2):  Comparison response (sleep disturbance) to pometone treatment with one 
week interval. P value <0.05 was considered as level of significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95% 
Confidence 
Interval 
 
P 
 
SD 
Mean 
Number of 
Sleep 
Disturbance 
 
No. 
 
 
Time 
 
-1.064-1.864 P>0.05 3.03 4.40 44 Before Pair  I 
2.94 4 44 1
st
 week 
-0.1641-2.764 P>0.05 2.94 4 44 1
st
 week Pair  2 
2.47 2.70 44 2
nd
 week 
-0.3741-2.554 P>0.05 2.47 2.70 44 2
nd
 week Pair 3 
1.95 1.61 44 3
rd
 week 
-1.074-1.854 P>0.05 1.95 1.61 44 3
rd
 week Pair  4 
1.80 1.22 44 4
th
 week 
1.716-4.644 P<0.001 3.03 4.40 44 Before  Pair  5 
1.80 1.22 44 4
th
 week 
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Figure (2): Comparison response (sleep disturbance) to treatment with one week 
interval . 
Discussion 
VMS are a disturbing part of menopause for many women and have a 
significant impact on the quality of life. Although hormone therapy is the most 
effective treatment for menopause related VMS, many women either cannot or do not 
wish to take this treatment. Therefore, the availability of effective alternative 
therapies for the treatment of VMS is of great importance such as phytoestrogens 
(Elena et al., 2012). Pomegranate is one of the only plants in nature known to contain 
the sex steroid estrone and has the highest botanical concentration of the steroid 
estrone at 14 mg/kg dried seed (Heftmann , 1966). Certain study  showed the  
comparison with the placebo group, participants in the promensil group were 
41%(isoflavones) but not in the rimostil group, thus 34% reduced hot flashes more 
rapidly (Tice  et al., 2003). In our study the visual analogue score for hot flush before 
treatment was 8.11±1.72 decrease to 1.36 ±2.10 after 4 weeks treatment with 
pometone.
 
While the score for sleep disturbances before treatment was 4.40±3.03 
decrease to 1.22 ±1.80 after 4 weeks treatment with pometone capsules.
 
The result of 
our study was in contrast to (Krebs et al., 2004) study, in which they found that 
phytoestrogens available as soy foods, soy extracts, and red clover extracts did not 
improve hot flushes or other menopausal symptoms.
 
In an Italian study involve 51 
women with severe hot flashes, the average number of hot flashes in the soy drinkers 
declined from 11 per day to six. In the placebo group it dropped from 11 to eight, 
which was statistically significant. But the soy had no effect on symptoms like 
anxiety, headaches or insomnia (David ,1999) 
Other study included 30 women who took 40 grams of crusted flax seed daily 
for 6 weeks. The mean decrease in the hot flash frequency was 50% from 7.3 to 3.6 
(Pruthi et al., 2007), in this study some side effects were recorded, 50% experienced 
mild or moderate abdominal distention, 30% of the them showed mild diarrhea and 
20%  did not complete the study because of side effects. While in our study there was 
no side effects of pometone, and no patient left the treatment because of side effects. 
Because phytoestrogens act similar to estrogen in certain tissues in the body, they 
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theoretically could increase the risk of  breast cancer, and overall safety required 
further assessment. Reassuringly, however, the authors in the Cochrane Database 
Systematic Review did not find evidence that treatment with phytoestrogens caused 
estrogenic stimulation of the endometrium when used for up to two years (Lethaby et 
al., 2007; Tice et al., 2006; Nelson et al., 2006) 
A recent review indicated that black cohosh root extract demonstrated good 
efficacy in relieving menopausal symptoms, such as vasomotor instability, with little 
or no toxicity (Hardy ,2000).  Another study showed that black cohosh had estrogen 
like activity and some efficacy in treating vasomotor menopausal symptoms, possibly 
by reducing the secretion of luteinizing hormone (Petho,1987).
 
Phytoestrogens 
formulations and herbal products may be attractive alternatives for perimenopausal 
and postmenopausal women who want to delay use of HRT because of concerns 
about estrogen’s effects on the progression of breast and uterine neoplasm and its 
tendency to increase coagulability (Lissin et al., 2000). 
 
However there is insufficient 
safety data exist to support long-term therapy with phytoestrogens and other herbal 
medications (Edyta et al., 2000) . 
 
Conclusions 
1. Pometone is effective, safe and cheap drug to reduce the hot flashes and sweating 
in perimenopausal and postmenopausal women.
 
2. Pometone also is effective in improvement of sleep disturbances in peri and 
postmenopausal women. 
3. No side effects of pometone were noted during the study. 
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